基于国家免疫规划登记数据的小儿肺炎球菌结合疫苗接种后神经与免疫不良事件研究
该研究基于韩国免疫登记与全国行政理赔数据链接,采用自控风险区间分析,纳入2018至2022年1,114,096名肺炎球菌结合疫苗受种者,评估2、4、6月龄三剂次接种后不良事件风险。结果显示除热性惊厥外,其他结局风险未增加;热性惊厥风险区间发生408例(56.0%),发病率比1.27(95%CI 1.10-1.47),绝对病例数少且预后良好。
要点
- 肺炎球菌结合疫苗除热性惊厥外未增加其他不良事件风险。
- 热性惊厥风险区间408例(56.0%),IRR 1.27(95%CI 1.10-1.47)。
- 热性惊厥绝对病例数少,通常自限且预后良好。
核心结论
- 肺炎球菌结合疫苗接种后除热性惊厥短暂风险增加外,其他潜在安全关注结局风险未增加。
- 热性惊厥绝对病例数少,通常自限且预后良好,不应妨碍父母或照护者接种疫苗。
研究设计与样本
- 基于韩国免疫登记数据与全国行政理赔数据链接的人群队列研究。
- 对2018至2022年有目标结局的肺炎球菌结合疫苗受种者进行自控风险区间分析。
- 采用条件泊松回归模型估计风险区间与对照区间的发病率比及95%置信区间。
主要发现
- 1,114,096名肺炎球菌结合疫苗受种者中,8,661例在风险或对照区间发生目标结局。
- 受种者第一剂次平均年龄10.0周,58.3%为男孩,85.3%接种13价肺炎球菌结合疫苗。
- 热性惊厥风险区间408例(56.0%),IRR 1.27(95%CI 1.10-1.47)。
- 过敏反应、哮喘、脑病、川崎病和血小板减少症风险未增加。
关键数值与推荐
- 风险区间与对照区间比较:热性惊厥IRR 1.27(95%CI 1.10-1.47),风险区间408例(56.0%)。
- 其他结局(过敏反应、哮喘、脑病、川崎病、血小板减少症)风险未增加。
临床怎么用
- 作者认为热性惊厥通常自限且预后良好,不应妨碍父母或照护者接种肺炎球菌结合疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the general consensus on the safety of pneumococcal conjugate vaccine (PCV), safety concerns unveiled during post-licensure surveillance need to be addressed. We investigated whether there is a transient increased risk following a three-dose series of pneumococcal conjugate vaccine (PCV) administered at 2, 4 and 6 months of age. METHODS: This was a population-based cohort study using the Korea immunization registry data linked to nationwide administrative claims data. Self-controlled risk interval analysis was conducted for PCV recipients who had an outcome of interest within pre-defined risk and control intervals between 2018 and 2022. The outcomes were anaphylaxis, asthma, encephalopathy, febrile seizure, Kawasaki disease and thrombocytopenia. We used conditional Poisson regression model to estimate the incidence rate ratios (IRRs) and 95% confidence intervals (CIs) comparing the outcomes in the risk and control intervals. RESULTS: Of 1 114 096 PCV recipients, 8661 had outcomes either in the risk or control intervals. Their mean age at Dose 1 was 10.0 weeks, 58.3% were boys, and 85.3% received 13-valent PCV. PCV was not associated with an increased risk of any outcomes except for febrile seizure. There were 408 (56.0%) cases of febrile seizure in the risk interval, corresponding to an IRR of 1.27 (95% CI 1.10-1.47). CONCLUSIONS: It is reassuring to note that there was no increased risk of the potential safety concerns following PCV administration. Despite the transient increased risk of febrile seizure, absolute numbers of cases were small. Febrile seizure is generally self-limiting with a good prognosis, and should not discourage parents or caregivers from vaccinating their children.
引用
- Kim JH, Yoon D, Lee H, et al. Neurological and immunological adverse events after pneumococcal conjugate vaccine in children using national immunization programme registry data. Int J Epidemiol. 2024. PMID: 38302750. doi:10.1093/ije/dyae010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。